To our shareholders and prospective investors,
Thank you for your continued interest in Innovacell as well as for your understanding and support of our work.
In my role as a leader of this company, there is a principle to which I consistently return: patients must always come first. While the pharmaceutical and biotechnology industry operates within a market economy, it is also one of the few industries that is deeply intertwined with the lives and health of the people it serves. We recognize the creation of shareholder value as an important responsibility, but we believe that such value is created as a result of consistently doing what is right for patients.
This patient-first mindset is reflected in Innovacell's development strategy. For example, our lead program, ICEF15, targets a condition that is not life threatening but has a profound impact on quality of life. For ICEF15, we have therefore adopted an approach that emphasizes the careful accumulation of sufficient clinical evidence through appropriately designed trials, with the goal of establishing data of unquestionable integrity. At the same time, for diseases with greater urgency or for rare and severe conditions, a different balance of risk, benefit, and development speed may be appropriate. Across all cases, what remains essential is making sound and responsible decisions based on the nature of the disease and the perspective of patients.
I also believe that trust cannot be built through numbers and metrics alone. While quantitative indicators are undeniably important, human progress has long been supported by belief, including belief in science, belief in collective effort, and belief that doing the right thing ultimately leads to the right outcome. Trust with patients, regulators, employees, and investors is earned through an honest engagement with both data and people, with theory and practice, and through a sincere commitment to responsibility.
As an American citizen born in Korea and raised in Japan from early childhood, Japan is not only where I live, but a place that has shaped my values as both an individual and a business leader. After studying in the United States, I have in recent years become deeply involved in Innovacell's journey, which is rooted in Austria. Through these experiences, I have come to appreciate the strengths of different cultures: the technical excellence cultivated in Austria, the discipline and balance that characterize Japanese organizations, and the dynamism that defines the United States. By bringing these strengths together, I hope to continue building a multinational and multifaceted organization with a strong sense of unity.
Innovacell stands on a foundation built through more than a quarter century of research, development, and challenge. With deep gratitude and a strong sense of responsibility toward those who have supported this journey, we remain committed to acting with integrity toward patients and society. We will continue striving to ensure that the value created through these efforts is shared with all who support Innovacell.
We sincerely appreciate your continued understanding and support.
Colin Novick
Co-CEO, Innovacell Inc.
